Investigational drug · Phase 3
LNS8801
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "LNS8801"
First trial start
2025
Aug 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LNS8801", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma (Skin Cancer)
- Melanoma Stage IIIB-IV
- Cutaneous Melanoma
- Unresectable Melanoma
Approved drugs for the same conditions: Melanoma · Oncology · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "LNS8801" as an intervention, largest first.
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive, not recruiting
Linnaeus Therapeutics, Inc.Industry
NCT04130516 · 200 participants (planned) · Start Oct 21, 2019 · Primary completion Jun 30, 2026
Drug: LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody · For: Solid Tumor, Adult
Sites: Los Angeles, California; New Haven, Connecticut; Boston, Massachusetts · 10 sites in all
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaPivotal-lookingRecruiting
Linnaeus Therapeutics, Inc.Industry
NCT06624644 · 135 participants (planned) · Start Aug 6, 2025 · Primary completion Feb 2029
Drug: LNS8801; Pembrolizumab and 4 more · For: Melanoma (Skin Cancer); Melanoma Stage IIIB-IV; Cutaneous Melanoma and 1 more
Sites: Newport Beach, California; San Francisco, California; Stanford, California · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Pregnancy-dependent cardioprotection via GPER activation in Dahl salt-sensitive rats with superimposed preeclampsia.
Alencar AKN, Swan KF, Manoharan MM, et al. · Am J Physiol Heart Circ Physiol 2025
- LNS-8801 as a therapeutic agent for aggressive lymphomas: ROS-induced cytotoxicity and synergy with existing therapies.
Li Y, Kosnopfel C, Schwammbach D, et al. · Blood Adv 2025
- Pregnancy-Dependent Cardioprotection via GPER Activation in Dahl Salt-Sensitive Rats.
Alencar AKN, Swan KF, Manoharan MM, et al. · bioRxiv 2025
- LNS8801: An Enantiomerically Pure Agonist of the G Protein-Coupled Estrogen Receptor Suitable for Clinical Development.
Natale CA, Mercado S, Zhuang R, et al. · Cancer Res Commun 2025
- An In Vivo Study of LNS8801, a GPER Agonist, in a Spontaneous Melanoma-Prone Mouse Model, TGS.
Marinaro C, Sauer J, Natale CA, et al. · Pigment Cell Melanoma Res 2025
- LNS8801: An enantiomerically pure agonist of the G protein-coupled estrogen receptor suitable for clinical development.
Natale CA, Mercado S, Zhuang R, et al. · bioRxiv 2024
Also in development for Melanoma (Skin Cancer)
- ipilimumab and nivolumabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
- nivolumab and relatlimabPhase 31 trial
Linnaeus Therapeutics, Inc. · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.